Sygnature Discovery

Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over employees, which includes 900 scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature Discovery has delivered 50 novel pre-clinical and 30 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more. Founded in 2004, we have delivered over 40 pre-clinical compounds, 21 clinical compounds, and our scientists are named on over 170 patent applications. We partner with global pharma, biotech, and NFP organizations, providing integrated drug discovery services from target identification through to candidate nomination. Our co-located teams are experts in protein science, chemistry, computational chemistry, in vitro biology, pharmacology, DMPK, form and formulation services, and project management, with a core therapeutic focus on oncology, inflammation and immunology, as well as neuroscience, metabolic diseases, respiratory, infectious diseases and fibrotic diseases.